Article
EGFR and KRAS mutations in metastatic lung adenocarcinomas.
Human pathology - 1 Oct 2011
Munfus-McCray Delicia, Harada Shuko, Adams Christina, Askin Frederic, Clark Douglas, Gabrielson Edward, Li Qing Kay
Abstract excerpt
In primary lung adenocarcinoma, EGFR and KRAS mutations are found in approximately 10% to 20% and 20% to 30%, respectively. Few studies have investigated these mutations in metastases. Patients with EGFR mutations have a 70% to 80% response rate to tyrosine-kinase inhibitors therapy and a longer progression-free survival rate in contrast to patients with KRAS mutations that are associated with virtually no...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.